ABDX - Ticker AI Digest

Abingdon Health Plc 📰 2
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (ABDX) 2
ABDX 06:02
Abingdon Health Plc
Trading Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health PLC, a leading med-tech contract service provider, released a trading update on January 15, 2026, highlighting significant growth and a positive outlook. Key points include
1. **Revenue Growth**H1 FY26 revenues increased by 45% to £4.5 million, driven by major commercial contracts secured over the past year.
2. **Cash Position**Cash and cash equivalents rose to £3.6 million at December 31, 2025, following a £3.2 million fundraise in October 2025 to support U.S. expansion and working capital needs.
3. **Outlook**The Board remains confident in the commercial outlook, maintaining FY26 revenue guidance of £12.6 million. Revenue is expected to be weighted towards H2 FY26, with anticipated profitability and positive operating cash flow.
4. **Contract Adjustments**Revenue from customer Find Out From Home (FOFH) is now expected in FY27 due to FOFH’s fundraising process, but this does not impact overall FY26 revenue expectations.
5. **U.S. Expansion**The Company is accelerating its lateral flow development and manufacturing capabilities in Madison, WI, to meet customer demand.
6. **Investor Presentation**Executive Chairman Dr. Chris Hand presented at the Proactive One2One Investor Forum on January 15, 2026, emphasizing the Company’s integrated CDMO and CRO service offerings and momentum in securing major contracts.
Abingdon Health continues to focus on its end-to-end services, regulatory support, and international expansion, positioning itself for sustained growth in the med-tech sector.
ABDX 06:01
Abingdon Health Plc
Appointment of NOMAD & Corporate Broker
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 1
ABDX 06:01
Abingdon Health Plc
European patent for AppDx® smartphone reader
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s and med-tech solutions, announced on December 18, 2025, the granting of a European patent (EP4150565) for its AppDx® lateral flow smartphone reader. This patent, titled "Assay Reading Method," complements existing patents in the USA and UK. AppDx® is a software development kit that enables the reading of colorimetric lateral-flow tests using smartphone cameras, providing qualitative and semi-quantitative results. The technology leverages image processing and deep learning algorithms tailored for each test. Dr. Chris Hand, Executive Chairman, highlighted the patent as a testament to Abingdon Healths innovation and its value to contract development and manufacturing customers. The company, founded in 2008 and headquartered in York, UK, specializes in lateral flow product development, regulatory support, and manufacturing services, with additional regulatory and analytical testing subsidiaries. This announcement was distributed via Reach, the non-regulatory press release service of the London Stock Exchange.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
ABDX 06:02
Abingdon Health Plc
Trading Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health PLC, a leading med-tech contract service provider, released a trading update on January 15, 2026, highlighting significant growth and a positive outlook. Key points include
1. **Revenue Growth**H1 FY26 revenues increased by 45% to £4.5 million, driven by major commercial contracts secured over the past year.
2. **Cash Position**Cash and cash equivalents rose to £3.6 million at December 31, 2025, following a £3.2 million fundraise in October 2025 to support U.S. expansion and working capital needs.
3. **Outlook**The Board remains confident in the commercial outlook, maintaining FY26 revenue guidance of £12.6 million. Revenue is expected to be weighted towards H2 FY26, with anticipated profitability and positive operating cash flow.
4. **Contract Adjustments**Revenue from customer Find Out From Home (FOFH) is now expected in FY27 due to FOFH’s fundraising process, but this does not impact overall FY26 revenue expectations.
5. **U.S. Expansion**The Company is accelerating its lateral flow development and manufacturing capabilities in Madison, WI, to meet customer demand.
6. **Investor Presentation**Executive Chairman Dr. Chris Hand presented at the Proactive One2One Investor Forum on January 15, 2026, emphasizing the Company’s integrated CDMO and CRO service offerings and momentum in securing major contracts.
Abingdon Health continues to focus on its end-to-end services, regulatory support, and international expansion, positioning itself for sustained growth in the med-tech sector.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 4
ABDX 06:02
Abingdon Health Plc
Trading Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health PLC, a leading med-tech contract service provider, released a trading update on January 15, 2026, highlighting significant growth and a positive outlook. Key points include
1. **Revenue Growth**H1 FY26 revenues increased by 45% to £4.5 million, driven by major commercial contracts secured over the past year.
2. **Cash Position**Cash and cash equivalents rose to £3.6 million at December 31, 2025, following a £3.2 million fundraise in October 2025 to support U.S. expansion and working capital needs.
3. **Outlook**The Board remains confident in the commercial outlook, maintaining FY26 revenue guidance of £12.6 million. Revenue is expected to be weighted towards H2 FY26, with anticipated profitability and positive operating cash flow.
4. **Contract Adjustments**Revenue from customer Find Out From Home (FOFH) is now expected in FY27 due to FOFH’s fundraising process, but this does not impact overall FY26 revenue expectations.
5. **U.S. Expansion**The Company is accelerating its lateral flow development and manufacturing capabilities in Madison, WI, to meet customer demand.
6. **Investor Presentation**Executive Chairman Dr. Chris Hand presented at the Proactive One2One Investor Forum on January 15, 2026, emphasizing the Company’s integrated CDMO and CRO service offerings and momentum in securing major contracts.
Abingdon Health continues to focus on its end-to-end services, regulatory support, and international expansion, positioning itself for sustained growth in the med-tech sector.
ABDX 06:01
Abingdon Health Plc
Appointment of NOMAD & Corporate Broker
ABDX 13:36
Abingdon Health Plc
Exercise of options and total voting rights
ABDX 06:01
Abingdon Health Plc
European patent for AppDx® smartphone reader
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s and med-tech solutions, announced on December 18, 2025, the granting of a European patent (EP4150565) for its AppDx® lateral flow smartphone reader. This patent, titled "Assay Reading Method," complements existing patents in the USA and UK. AppDx® is a software development kit that enables the reading of colorimetric lateral-flow tests using smartphone cameras, providing qualitative and semi-quantitative results. The technology leverages image processing and deep learning algorithms tailored for each test. Dr. Chris Hand, Executive Chairman, highlighted the patent as a testament to Abingdon Healths innovation and its value to contract development and manufacturing customers. The company, founded in 2008 and headquartered in York, UK, specializes in lateral flow product development, regulatory support, and manufacturing services, with additional regulatory and analytical testing subsidiaries. This announcement was distributed via Reach, the non-regulatory press release service of the London Stock Exchange.

AI Crunch

Single-Ticker AI Crunch
ABDX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Abingdon Health Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for ABDX on 2026-01-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
21781004
Enterprise Value
4187469
Public Float
66.76
Broker Target
19
Shares Out
251077850
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890000.0
Cash
1918000.0
EPS
-0.01
Net Income
-3415000.0
Revenue
8429000.0
Enterprise Value
4187469
Trailing PE
-
Forward PE
53.1915
Price Sales TTM
2.2755
Price Book MRQ
3.1878
EV Revenue
1.8102
EV EBITDA
-0.2499

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

2 live catalysts just hit ABDX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-01-15 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
2 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow feeding the chart narrative.
06:01 Today's Catalyst Appointment of NOMAD & Corporate Broker
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 1.54%
RSI Gauge
Price Change
AI Forecast